Lifecore Biomedical, Inc. (LFCR) P/E Ratio History
Deep ValueTrading at -4.1x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 2004–2025
Loading P/E history...
P/E Ratio Analysis
As of June 29, 2026, Lifecore Biomedical, Inc. (LFCR) trades at a price-to-earnings ratio of -4.1x, with a stock price of $5.17 and trailing twelve-month earnings per share of $-0.91.
The current P/E is 104% below its 5-year average of 101.3x. Over the past five years, LFCR's P/E has ranged from a low of 14.2x to a high of 1458.8x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.0x, LFCR trades at a 118% discount to its sector peers. The sector includes 231 companies with P/E ratios ranging from 0.0x to 191.4x.
Relative to the broader market, LFCR trades at a notable discount to the S&P 500 median P/E of 25.3x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our LFCR DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
LFCR Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
LFCR P/E vs Peers
Contract development and manufacturing services peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $993M | 157.8 | - | +107%Best | |
| $9B | 29.3Lowest | 1.27Best | -25% | |
| $17B | 30.5 | - | -25% | |
| $13B | 31.6 | - | +1% | |
| $4B | 33.7 | - | +5% | |
| $4B | 5043.2 | - | +101% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
LFCR Historical P/E Data (2004–2025)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q1 | Aug 25 2024 | $6.00 | $0.06 | 100.0x | +95% |
| FY2024 Q4 | May 26 2024 | $5.62 | $0.24 | 23.4x | -54% |
| FY2019 Q4 | May 31 2019 | $9.92 | $0.01 | 1458.8x | +2746% |
| FY2019 Q3 | - | $12.84 | $0.24 | 54.5x | +6% |
| FY2019 Q2 | Nov 30 2018 | $15.41 | $0.79 | 19.6x | -62% |
| FY2019 Q1 | Aug 31 2018 | $13.45 | $0.82 | 16.3x | -68% |
| FY2018 Q4 | - | $14.10 | $0.90 | 15.7x | -69% |
| FY2018 Q3 | Feb 28 2018 | $13.00 | $0.76 | 17.0x | -67% |
| FY2018 Q2 | - | $12.50 | $0.31 | 39.7x | -23% |
| FY2018 Q1 | - | $13.00 | $0.35 | 37.6x | -27% |
| FY2017 Q4 | May 31 2017 | $14.00 | $0.39 | 36.1x | -30% |
| FY2017 Q3 | - | $12.60 | $0.47 | 26.9x | -48% |
| FY2016 Q2 | Nov 30 2015 | $12.81 | $0.47 | 27.3x | -47% |
| FY2016 Q1 | Aug 31 2015 | $13.30 | $0.52 | 25.6x | -50% |
| FY2015 Q4 | May 31 2015 | $14.29 | $0.50 | 28.6x | -44% |
| FY2015 Q3 | Feb 28 2015 | $13.96 | $0.52 | 26.8x | -48% |
| FY2015 Q2 | Nov 30 2014 | $13.14 | $0.62 | 21.2x | -59% |
| FY2015 Q1 | Aug 31 2014 | $13.13 | $0.63 | 20.8x | -59% |
| FY2014 Q4 | May 31 2014 | $12.01 | $0.72 | 16.7x | -67% |
| FY2014 Q3 | Feb 28 2014 | $10.19 | $0.72 | 14.2x | -72% |
| FY2014 Q2 | Nov 30 2013 | $11.74 | $0.66 | 17.8x | -65% |
| FY2014 Q1 | Aug 31 2013 | $13.20 | $0.87 | 15.2x | -70% |
| FY2013 Q4 | May 31 2013 | $14.04 | $0.79 | 17.8x | -65% |
| FY2013 Q3 | - | $11.01 | $0.73 | 15.1x | -70% |
| FY2013 Q2 | Nov 30 2012 | $10.06 | $0.73 | 13.8x | -73% |
| FY2013 Q1 | Aug 31 2012 | $9.80 | $0.52 | 19.0x | -63% |
| FY2012 Q4 | - | $7.31 | $0.49 | 14.9x | -71% |
| FY2012 Q3 | Feb 29 2012 | $6.30 | $0.28 | 22.5x | -56% |
| FY2012 Q2 | Nov 30 2011 | $5.95 | $0.19 | 31.3x | -39% |
| FY2012 Q1 | Aug 31 2011 | $5.95 | $0.14 | 43.1x | -16% |
| FY2011 Q4 | - | $5.74 | $0.16 | 37.0x | -28% |
| FY2011 Q3 | Feb 28 2011 | $6.15 | $0.20 | 30.7x | -40% |
| FY2011 Q2 | - | $6.26 | $0.18 | 35.6x | -31% |
| FY2011 Q1 | - | $5.50 | $0.16 | 35.2x | -31% |
| FY2010 Q4 | May 31 2010 | $6.19 | $0.15 | 41.5x | -19% |
| FY2010 Q3 | Feb 28 2010 | $6.06 | $0.29 | 21.0x | -59% |
| FY2010 Q2 | Nov 30 2009 | $6.28 | $0.28 | 22.2x | -57% |
| FY2010 Q1 | Aug 31 2009 | $6.11 | $0.28 | 21.4x | -58% |
| FY2009 Q4 | May 31 2009 | $6.78 | $0.32 | 21.5x | -58% |
| FY2009 Q3 | Feb 28 2009 | $4.76 | $0.36 | 13.2x | -74% |
| FY2009 Q2 | Nov 30 2008 | $6.94 | $0.45 | 15.4x | -70% |
| FY2009 Q1 | Aug 31 2008 | $9.39 | $0.51 | 18.4x | -64% |
| FY2008 Q4 | May 31 2008 | $8.01 | $0.51 | 15.7x | -69% |
| FY2008 Q3 | Feb 29 2008 | $9.38 | $0.54 | 17.4x | -66% |
| FY2008 Q2 | Nov 30 2007 | $13.14 | $1.31 | 10.0x | -80% |
| FY2008 Q1 | Aug 31 2007 | $13.50 | $1.19 | 11.3x | -78% |
| FY2007 Q4 | - | $13.60 | $1.08 | 12.5x | -76% |
| FY2007 Q3 | Feb 28 2007 | $13.38 | $1.19 | 11.2x | -78% |
| FY2007 Q2 | - | $9.58 | $0.40 | 23.7x | -54% |
| FY2007 Q1 | - | $10.13 | $0.36 | 28.3x | -45% |
| FY2006 Q4 | May 31 2006 | $8.59 | $0.34 | 25.6x | -50% |
| FY2006 Q3 | - | $7.25 | $0.26 | 28.3x | -45% |
| FY2006 Q2 | Nov 30 2005 | $7.37 | $0.22 | 34.2x | -33% |
| FY2006 Q1 | Aug 31 2005 | $6.54 | $0.22 | 29.2x | -43% |
| FY2005 Q4 | - | $6.00 | $0.22 | 27.8x | -46% |
| FY2005 Q3 | Feb 28 2005 | $6.89 | $0.22 | 31.9x | -38% |
| FY2005 Q2 | - | $6.32 | $0.16 | 40.5x | -21% |
| FY2005 Q1 | - | $4.75 | $0.12 | 41.1x | -20% |
| FY2004 Q4 | May 31 2004 | $7.06 | $0.12 | 60.9x | +19% |
| FY2004 Q3 | Feb 29 2004 | $8.02 | $0.11 | 75.7x | +48% |
Average P/E for displayed period: 51.3x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
22+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
LFCR — Frequently Asked Questions
Quick answers to the most common questions about buying LFCR stock.
What is LFCR's P/E ratio?
Lifecore Biomedical, Inc. (LFCR) trailing twelve-month P/E ratio is -4.1x, based on TTM diluted EPS of $-0.91. The 5-year average P/E is 101.3x and the historical range spans 14.2x to 1458.8x.
Is LFCR stock overvalued or undervalued?
LFCR trades at -4.1x P/E, below its 5-year average of 101.3x. At the 0th percentile of its historical range (14.2x–1458.8x), the stock is priced at a discount to its own history.
Is LFCR stock expensive?
No, LFCR is not expensive on a historical basis. The current P/E of -4.1x is below the 5-year average of 101.3x and sits at the 0th percentile of its valuation range.
What is LFCR's historical P/E range?
Over the past 5 years, LFCR's P/E ratio has ranged from 14.2x to 1458.8x, with a median of 26.8x and an average of 101.3x. The current P/E of -4.1x places the stock at the 0th percentile of this range. Full historical data spans 2004–2025.
How does LFCR's P/E compare to the S&P 500?
LFCR trades at -4.1x P/E versus the S&P 500 median of 25.3x. The 116% discount to the market suggests lower growth expectations or perceived higher risk.
How does LFCR's valuation compare to Healthcare peers?
Lifecore Biomedical, Inc. P/E of -4.1x compares to the Healthcare sector median of 23.0x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is LFCR's PEG ratio?
LFCR PEG ratio is N/A, based on a P/E of -4.1x and EPS growth of -484.8%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is LFCR's earnings yield?
LFCR earnings yield is N/A, the inverse of its -4.1x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.